Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 8/20 | 0.59 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8235376 | 0.89 | RAD52 (0.55) | S1PR3POLBMAPTNPSR1 | |
| SCHEMBL336644 | 0.89 | PLA2G2A (0.61) | S1PR3PLA2G2APOLB | |
| SCHEMBL337559 | 0.85 | S1PR3 (0.51) | S1PR3PLA2G2A | |
| SCHEMBL10075560 | 0.84 | S1PR3 (0.51) | S1PR3PLA2G2APOLBMAPTNPSR1 | |
| SCHEMBL336487 | 0.83 | S1PR3 (0.50) | S1PR3PLA2G2APOLBMAPTNPSR1 | |
| SCHEMBL291421 | 0.81 | S1PR3 (0.65) | S1PR3PLA2G2AMAPT | |
| SCHEMBL337183 | 0.81 | PLA2G2A (0.59) | S1PR3PLA2G2APOLBMAPT | |
| SCHEMBL3726839 | 0.80 | S1PR3 (0.67) | S1PR3PLA2G2A | |
| SCHEMBL337115 | 0.79 | S1PR3 (0.61) | S1PR3POLB | |
| SCHEMBL337189 | 0.79 | PLA2G2A (0.64) | S1PR3PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007112322-A2 | INDOLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | S1PR1, S1PR2, S1PR3 | S1PR3 3/4885PLA2G2A 630/4885POLB 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.